CODEXIS, INC. (CDXS)

Current Report Filed: 2026-05-07

Codexis announced Q1 2026 financial results on May 7, 2026, with the detailed press release furnished as Exhibit 99.1, though specific financial metrics are not disclosed in this 8-K wrapper document.
The filing was signed by Georgia Erbez, CFO and Chief Business Officer, indicating active financial leadership during the earnings announcement period.
This is a routine quarterly earnings disclosure filed under Item 2.02 (Results of Operations and Financial Condition), with the press release explicitly not deemed 'filed' for liability purposes under Section 18 of the Securities Exchange Act.

Quarterly Report Filed: 2026-05-07

The filing shows CDXS operates across three geographic segments (Americas, APAC, EMEA) with revenue diversification across product and R&D revenue streams, indicating a balanced business model with multiple revenue sources.
The company maintains significant unbilled receivables (both short-term and long-term) as of Q1 2026, suggesting strong contract backlog and future revenue recognition potential from existing customer commitments.
CDXS holds a diversified investment portfolio including money market funds, commercial paper, corporate debt securities, and U.S. Treasury securities with Level 1 and Level 2 fair value inputs, demonstrating prudent cash management and liquidity preservation.
The presence of multiple equity compensation instruments (stock compensation plans, warrants, and employee stock options) reflects a growth-stage company strategy to attract and retain talent while managing cash burn.

Current Report Filed: 2026-04-14

Dennis Wolf has resigned from the Codexis board and its committees, citing no disagreement with the company.
The board has rebalanced the membership among the classes of directors, moving one director from Class II to Class III.
Esther Martinborough, Ph.D. has resigned from the board and been re-elected to the Class III director role, maintaining her committee memberships.

Current Report Filed: 2026-03-11

Codexis reported their financial results for the quarter and year ended December 31, 2025, which will be of interest to investors.
The company did not provide any updated financial guidance or outlook, which may be a concern for investors looking for forward-looking information.
There were no material agreements, leadership changes, or other notable events disclosed in the 8-K filing.

Annual Report Filed: 2026-03-11

Codexis experienced steady revenue growth across its product and research and development segments over the past three years, indicating strong demand for its technology solutions.
The company's research and development revenue from key customers like Merck, Nestle, and Novartis has been a significant driver of overall revenue, suggesting successful partnerships and collaborations.
Codexis has maintained a healthy balance sheet with increasing cash and cash equivalents, which could support future investments and strategic initiatives.

Insider Trading Filed: 2026-02-09

Alison Moore, the President and CEO of Codexis, Inc. (CDXS), sold 3,826 shares of common stock on February 6, 2026 to satisfy tax or other government withholding obligations in connection with the vesting of her restricted stock units (RSUs).
After the sale, Moore continues to hold 250,506 shares of Codexis common stock, including 136,249 RSUs, indicating she retains a significant stake in the company.
The sale price of $1.3071 per share suggests the transaction was conducted at or near the market price at the time, rather than a large insider sell-off.

Insider Trading Filed: 2026-02-09

Insider Georgia Erbez, the Chief Financial Officer and Chief Business Officer, sold 3,826 shares of Codexis Inc (CDXS) at an average price of $1.3071, likely to satisfy tax or other government withholding obligations related to the vesting of restricted stock units.
Erbez continues to hold 66,810 shares, including 24,374 restricted stock units, suggesting ongoing commitment to the company.
The sale represents a small portion of Erbez's total holdings and may not indicate a significant change in her long-term outlook for the company.

Insider Trading Filed: 2026-02-09

The Chief Scientific Officer of Codexis, Inc. sold 2,492 shares of the company's common stock at $1.3071 per share, likely to satisfy tax or other government withholding obligations.
The reporting person still holds 136,283 shares of Codexis, Inc. common stock, including 35,799 restricted stock units.
The transaction appears to be a routine sale of shares to cover tax obligations and not an indication of a significant change in the insider's position or confidence in the company.

Insider Trading Filed: 2026-01-08

The reporting person, Stefan Lutz, who is the Chief Scientific Officer (CSO) of Codexis, Inc., sold 4,685 shares of the company's common stock at an average price of $1.6968 per share.
The sale was made to cover tax liability incurred due to the vesting and release of Restricted Stock Units held by the reporting person, indicating the transaction was a routine stock sale for tax purposes.
The reporting person still holds 138,775 shares of Codexis common stock, including 41,633 restricted stock units, suggesting they maintain a significant ownership stake in the company.

Important Information